Injective (INJ) is showing renewed momentum after forming a stable base in the $3–4 range, with traders closely monitoring whether the upward move can overcome several key resistance levels. Technical indicators currently reflect a constructive outlook, though INJ is now trading near the upper Bollinger Band, suggesting that volatility could remain elevated in the near term.
Injective surges past $1 billion in tokenized assets, targets $15 resistance
Technical Recovery and Resistance Levels
INJ has recently achieved a technical recovery following consolidation near $4, which began in late August, according to chart data from TradingView. The token staged a notable rally in September, advancing through several resistance zones and reaching approximately $8.40 before settling near $7.93.
Technical analysis places immediate focus on the $8.59 area around the upper Bollinger Band, with any sustained breakout potentially targeting the $10 level. On the downside, $6.62 marks the middle band and could serve as an important support reference.
The Moving Average Convergence Divergence (MACD) indicator remains constructive, as the MACD line stays above the signal line in the positive region. However, the MACD histogram now shows signs of waning intensity, pointing to a possible loss of momentum. Despite this, the broader short-term structure remains supportive for the current recovery phase.
For traders, the main technical focus is on whether INJ can sustain movement above $8.59. Failing that, attention turns to $6.62 as the next significant support.
| $8.40–$8.59 | Immediate resistance (upper Bollinger Band) |
| $10 | Technical upside target |
| $15 | Major weekly resistance |
| $6.62 | Middle Bollinger Band, support |
Injective’s Growth in Real-World Asset Tokenization
Beyond price action, Injective has rapidly expanded its ecosystem. The protocol announced that the total value of tokenized assets on its platform now exceeds $1 billion, reflecting robust growth in real-world asset (RWA) activity. Tokenization continues to gain importance in bridging traditional finance and blockchain networks.
With over $1 billion in tokenized assets, the Injective ecosystem reinforces its role as a significant player in the trend toward real-world asset integration on blockchain.
Injective’s ecosystem also introduced Injective Mint, a feature designed to enable developers to bring a broader range of assets onto the blockchain. This aims to lower barriers for real-world asset tokenization and further drive ecosystem adoption.
INJ’s market moves are not directly influenced by these ecosystem advances in the short term. However, the developments highlight growing utility in the project’s infrastructure and may support long-term relevance.
Mini dictionary: Real-world asset (RWA) tokenization refers to the process of representing traditional assets such as real estate, commodities, or securities on the blockchain through digital tokens. This enables fractional ownership, enhanced liquidity, and programmatic transfers without conventional intermediaries.
Progress in European Regulatory Compliance
Injective also achieved a milestone by submitting its Markets in Crypto-Assets (MiCA) whitepaper, which is now listed on the European Securities and Markets Authority (ESMA)’s Interim MiCA Register. This marks a significant step toward regulatory compliance, potentially paving the way for regulated access to INJ across 30 European Union countries.
The move positions Injective for broader availability in Europe as regulations governing digital assets become clearer. These regulatory efforts are separate from day-to-day price fluctuations but remain essential for long-term project expansion and institutional adoption.
Injective is a decentralized finance (DeFi) protocol offering a layer-1 blockchain focused on interoperability and the tokenization of both blockchain-native and real-world assets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ImmunityBio stock surges 6.91% to close at $9.44, touches $10 intraday for first time since March
Citi Expands Stablecoin Integration Into Traditional Financial Infrastructure
Altcoin MCap MACD Flips Bullish After 19 Months: 5 Coins Worth Buying Before the Next Rally

Micron's earnings report dazzles, but stock price remains "unmoved"! Wall Street remains optimistic, with the highest target price set at $1,625
Micron's performance and guidance were both strong, but its share price has already surged 237% this year, resulting in a muted pre-market reaction. Wall Street giants such as Deutsche Bank, Bank of America, Goldman Sachs, and JPMorgan remain collectively bullish—26 long-term strategic customer agreements have secured visibility for profits. UBS has even set a top target price of $1,625, strongly affirming Micron's cross-cycle profitability and robust upside potential.
